

BODY COMPOSITION AND BONE METABOLISM IN YOUNG GAUCHER DISEASE TYPE I PATIENTS TREATED WITH IMIGLUCERASE

M. S. Parisi*, S. R. Mastaglia**, A. Bagur, G. Goldstein, S. N. Zeni*, B. Oliveri*

Sección Osteopatías Médicas, Hospital de Clínicas, Universidad de Buenos Aires, Argentina

Abstract

Bone involvement is one of the most disabling complications in patients with type 1 Gaucher disease (GDI) and its pathophysiology is yet to be fully understood. It is well known that body composition is a determinant of bone mass. Previous reports indicating disturbance in glucose and lipid metabolism in GDI patients suggested a possible alteration in body composition in this group of patients.

Objective: To analyze body composition, bone mass and turnover in young adults with GDI receiving enzyme replacement therapy (ERT).

Population: 5 women and 4 men with GDI aged ($X \pm SD$) 26.9 ± 6.9 years, receiving imiglucerase in a mean dose of 53 ± 13 IU/kg/2weeks, during 4.9 ± 3.9 years; and 145 sex and age matched healthy adults agreed to participate in the study. All control subjects had a body mass index (BMI) between 20 and 25 kg/m².

Methods: Total body dual X-ray absorptiometry (DXA) was used to measure body composition and bone mass. Serum creatinine, calcium, osteocalcin (BGP), and type I collagen beta carboxy-terminal telopeptide (β CTX) were determined in patients and controls. In addition, 25 hydroxyvitamin D (25OHD), and chitotriosidase activity were measured in patients.

Results: GDI patients presented statistically significant ($p < 0.01$) lower BMI, bone mineral density (BMD), bone mineral content (BMC), lean mass (LM), and fat mass (FM), compared to controls. LM correlated positively with BMC and BMD in both groups ($p < 0.01$). GDI patients receiving the lower dose of ERT (< 60 IU/kg/2weeks) presented lower BMD values than those receiving the higher dose (≥ 60 IU/kg/2weeks) (0.968 ± 0.032 vs 1.088 ± 0.061 g/m², respectively, $p < 0.001$). Mean BGP levels were similar in patients and controls, whereas β CTX levels were higher in GDI patients ($p < 0.02$). All patients presented deficiency levels (< 30 ng/ml) of 25OHD.

Conclusions: Although the patients had been receiving ERT, they presented a significant diminution in all body composition parameters, the decrease was more evident in those receiving the lower dose. The reduc-

tion in bone mass was associated with an imbalance in bone turnover (increased bone resorption). The correlation between LM and bone mass, suggests that metabolic disturbance occurring in GDI patients may be indirectly responsible for bone mass reduction in GDI patients, by altering body composition.

Key words: Gaucher disease, bone turnover markers, bone mineral density, imiglucerase, body composition, DXA.

Abbreviations: Type I Gaucher disease (GDI), lean mass (LM), fat mass (FM), bone mineral density (BMD), bone mineral content (BMC), enzyme replacement therapy (ERT), osteocalcin (BGP), type I collagen beta carboxy-terminal telopeptide (β CTX), body mass index (BMI)

INTRODUCTION

Gaucher disease is the most common lysosomal storage disorder (Meikle et al. 1999). It is the result of genetic mutations, which cause a deficiency in the level of activity of lysosomal enzyme β -glucocerebrosidase (acid β -glucosidase) leading to the accumulation of glucosylceramide within the monocytes and macrophages of various organ systems. The affected organs include the spleen, liver, lung, kidneys, bone and bone marrow (Koprivica et al. 2000). Three basic clinical forms have been differentiated according to the degree of neurological involvement. The nonneuropathic form, or type I Gaucher disease (GDI), is the most common form. The remaining forms are the acutely neuropathic form (type II) and the subacutely neuropathic form (type III) (Koprivica et al. 2000). The choice treatment for this disease is enzyme replacement therapy (ERT) with β -glucocerebrosidase, derived from human placenta (alglucerase) or from recombinant DNA production (imiglucerase) (Cohen et al. 1998; Fiore et al. 2002).

Eighty percent of patients with GDI present skeletal involvement (bone crises, nonspecific bone pain, bone marrow infiltration, osteopenia, pathologic fractures, impairment of remodeling, osteosclerosis and/or osteonecrosis), all of which are disabling complications with a negative impact on the patient's quality of life (Stowens et al. 1985; Wenstrup et al. 2002). Three different pathological processes are known to contribute to the skeletal manifestations in patients with

* Researcher of the National Council for Scientific and Technological Research (CONICET), Argentina

** Fellow of the National Council for Scientific and Technological Research (CONICET), Argentina.

GDI: 1) focal disease (osteonecrosis and osteosclerosis); 2) local disease (cortical thinning and long bone deformity) and 3) generalized osteopenia (resulting from abnormally high rates of bone resorption and reduced rates of bone formation) (Wenstrup et al. 2002). The clinical course of Gaucher disease varies greatly among individual patients and bone involvement is perhaps the most variable manifestation of the disease. Previous studies disclosed uniformly a significant reduction in bone mass in GDI child and adult patients (Fiore et al. 2002; Rosenthal et al. 1995; Pastores et al. 1996; Bembi et al. 2002; Ciana et al. 2003). The beneficial effect of ERT on bone mineral density (BMD) has been demonstrated only in long-term follow-up studies (4.5 years or more) (Lebel et al. 2004; Ciana et al. 2005; Wenstrup et al. 2007). Studies assessing biochemical markers of bone turnover, a helpful tool to study skeletal metabolism, have shown controversial results, reporting decreased, normal or increased bone markers, both in patients with and without ERT (Fiore et al. 2002; Drugan et al. 2002; Schiffman et al. 2002; Ciana et al. 2003; Ciana et al. 2005).

There are reports indicating that patients with Gaucher disease present metabolic disturbance evidenced by alterations in their serum lipid profile (Cenarro et al. 1999; Alfonso et al. 2003), increased glucose production, and increased resting energy expenditure (REE) (Corrsmitt et al. 1995; Holak et al. 1997). Therefore, body composition might be affected. Many studies have demonstrated that parameters of body composition (i.e. lean mass and fat mass) influence bone mass (Reid et al. 1992; Michaelsson et al. 1996; Sundeep et al. 1996; Baumgartner et al. 1996; Proctor et al. 2000; Pluijm et al. 2001; Matsuo et al. 2003; Lim et al. 2004; Makovey et al. 2005; Walsh et al. 2006). To our knowledge there are no reports evaluating body composition of GDI patients by means of dual X-ray absorptiometry (DXA).

Based on the above, the aim of this cross-sectional study was to analyze body composition, bone mass and bone turnover in young adult GDI patients receiving ERT.

MATERIAL AND METHODS

PATIENTS

Nine young adult patients with GDI, 5 females (aged 22 to 27 years) and 4 males (aged 21 to 43 years), were studied. Diagnosis was confirmed by the presence of low acid b-glucosidase activity in leucocytes and the absence of disease involving the central nervous system. Mean age of patients was 26.9 ± 6.9 years ($X \pm SD$) and their body mass index was 19.9 ± 1.8 kg/m² (range: 17-24 kg/m²). All patients had been receiving ERT (imiglucerase) in a mean dose of 53 ± 13 IU/kg/2weeks (range: 30-71 IU/kg/2weeks) for 4.9 ± 3.9 years (range: 1.3-11.7 years). The mean total accumulated dose of ERT was 6.434 ± 5.501 IU/kg (range: 1.476-15.600 IU/kg). The patients had never received medication known to affect bone homeostasis (i.e., oral corticosteroids, fluoride, calcitonin, or bisphosphonates).

CONTROLS

Ninety-four sex and age matched healthy adults, 34 females aged 24.4 ± 2.5 years (range: 20-29 years), and 60 males aged 32.7 ± 8.4 years (range: 21-49 years), agreed to participate in the study as controls for bone markers.

Fifty-one sex and age matched healthy adults, 11 females aged 25.1 ± 2.2 years (range: 21-28 years), and 40 males aged 33.2 ± 9.8 years (range: 20-49 years), agreed to participate in the study as controls for bone mass and body composition assessment. All control subjects presented body mass index (BMI) values between 20 and 25 kg/m².

None of the control subjects had a history of disease or had taken drugs known to affect bone metabolism.

The protocol was approved by the Ethics Committee of the Hospital de Clínicas, and written informed consent was given by both patients and controls.

CLINICAL EVALUATION

A questionnaire including personal data, history of splenectomy, and history of bone involvement (bone pain and crises, pathological fractures, and osteonecrosis) was answered by patients. The presence of hepatomegaly was evaluated qualitatively using different available methods (ultrasound, computed tomography or physical examination). Anthropometric measurements were performed in patients and controls using standard techniques.

BONE MASS AND BODY COMPOSITION

Total body bone mineral density (BMD), bone mineral content (BMC), fat mass (FM) and lean mass (LM) were measured using DXA (Lunar DPX). Technical details, coefficients of variation (CV) and normal values are reported elsewhere (Vega et al. 1993; Oliveri et al. 1999; Wittich et al. 2001).

LABORATORY TESTS

Overnight fasting blood samples were taken before 10 am. The following serum laboratory tests were performed in GDI patients: calcium (sCa) (reference value (RV): 8.9-10.4 mg/dl), creatinine (sCr) (RV: 0.5-1.4 mg/dl), 25 hydroxyvitamin D (25OHD) (desirable level: over 30 ng/ml), (Dawson-Hughes et al. 2005), and chitotriosidase activity (Ch-Pl) (RV: 0.05-1.00 mmol/min/ml). Serum osteocalcin (BGP) (RV: 11-46 ng/ml) was measured as a marker of bone formation, whereas serum type I collagen beta carboxy-terminal telopeptide (β CTX) was assessed as a marker of bone resorption, in patients and controls. sCr and sCa, were determined following standard methods (Zeni et al. 2001). Levels of 25OHD were assessed using the I¹²⁵ radioimmunochemical method (RIE) (Diasorin Inc., Minnesota, USA). β CTX and BGP levels were determined employing Electrochemoluminescence (Elecsys Roche Diagnostics Penzberg, Germany). Activity of Ch-Pl was assessed in 8 of the 9 patients by means of a fluorometric method.

STATISTICS

All studied variables are presented as mean \pm standard deviation. Statistical analyses were performed using SPSS 11.0 for Windows. Mann-Whitney test was used to compare values corresponding to patients and controls, and to compare patients according to the current dose of ERT (≥ 60 IU/kg/2weeks vs < 60 IU/kg/2weeks). Rho Spearman correlations were calculated to analyze relationships among laboratory values, bone mass, body composition and ERT. A value of $p < 0.05$ was considered significant.

RESULTS

The clinical characteristics of GDI patients are described in Table 1.

Prior to ERT, history of unspecific bone pain was reported in all patients, bone crises in 5, bone fracture in 2, and osteonecrosis (avascular femoral necrosis) in 3. After initiating ERT, one patient suffered a bone crisis and one patient had a bone fracture; bone pain decreased in six patients, increased in one, and remained unchanged in the remaining two.

Table 1. Characteristics of young type 1 Gaucher disease patients treated with enzyme replacement therapy.

Patient	Sex	Age (years)	Weight (kg)	Height (m)	BMI (kg/m ²)	ERT			Splenoctomy	Hepatomegaly
						Current Dose (IU/kg/2w)	Duration of treatment (years)	Total accumulated dose (IU/kg)		
1	M	32	61	1.61	24	60	1.3	1888	+	+
2	M	43	53	1.64	20	60	1.7	2400	-	-
3	M	21	52	1.62	20	60	11.7	15120	+	-
4	M	25	71	1.86	21	60	5.2	7440	-	-
5	F	23	54	1.60	21	60	10.9	15600	+	+
6	F	27	41	1.55	17	30	3.0	2160	+	-
7	F	25	45	1.53	19	71	3.0	5112	-	+
8	F	24	47	1.53	20	43	6.5	6708	-	+
9	F	22	49	1.63	18	41	1.5	1476	-	+

M: male, F: female, BMI: body mass index, ERT: enzyme replacement therapy (imiglucerase).




Fig. 1. Body composition in Gaucher disease type I (GDI) patients and healthy sex and age matched controls. BMD: bone mineral density, BMC: bone mineral content, LM: lean mass, FM: fat mass. * $p < 0.01$, ** $p < 0.001$.




Fig. 2. Correlation between lean mass and bone mineral density -dotted lines- and between lean mass and bone mineral content -dashed lines-, A) in healthy sex and age matched controls; B) in Gaucher disease type I patients (GDI). LM: lean mass; BMD: bone mineral density; BMC: bone mineral content.

BONE MASS AND BODY COMPOSITION

We observed that GDI patients had significantly lower BMI (19.9 ± 1.8 vs 22.9 ± 1.9 kg/m², $p<0.001$), BMD (1.048 ± 0.079 vs 1.199 ± 0.088 g/m², $p<0.001$), BMC (2175 ± 477 vs 2902 ± 465 g, $p<0.001$), LM (40293 ± 8977 vs 49685 ± 7741 g, $p<0.01$), and FM (8983 ± 3493 vs 14643 ± 4082 g, $p<0.001$) compared to controls (Fig. 1).

In both groups, GDI patients and controls, LM correlated significantly with bone mass parameters (Fig. 2). In contrast, FM did not correlate with bone mass in either the control or GDI group (data not shown).

Comparisons among patients, divided according to the current dose of imiglucerase (<60 vs ≥ 60 IU/kg/2 weeks), showed that BMD was $\sim 11\%$ lower

in those receiving the lower dose ($p<0.05$). As regards body composition analysis, a decrease in BMC and LM ($\sim 21\%$ and $\sim 23\%$, respectively), and $\sim 5.5\%$ increase in FM was observed in individuals receiving the lower dose but the differences failed to reach statistical significance (Fig. 3).

LABORATORY TESTS

All patients had levels of sCr (0.64 ± 0.15 g/dl), and sCa (9.1 ± 0.4 mg/dl) within the normal reference values. However, mean sCr levels were lower in GDI patients compared to controls (0.85 ± 0.19 g/dl), $p<0.01$. High levels of Ch-P1 activity (103.5 ± 77.1 mmol/min/ml; range: 34.4-243.61 mmol/min/ml) were found in the 8 studied patients. Values of




Fig. 3. Body composition according to the current imiglucerase dose: <60IU/kg/2weeks (n = 3) –white columns-, and ≥60IU/kg/2 weeks (n = 6) –grey columns-. BMD: bone mineral density; BMC: bone mineral content; FM: fat mass; LM: lean mass. *p<0.05.

25OHD (22.3 ± 3.0 ng/ml) were below the hypothetical desirable level of 30 ng/ml (Dawson-Hughes et al. 2005) in all patients.

Biochemical determinations of bone markers corresponding to patients and controls showed that β CTX was higher in GDI patients than controls (677 ± 293 vs 433 ± 180 ng/l, $p < 0.02$), but BGP levels were similar in both groups (24.6 ± 13.7 vs 26.4 ± 9.8 ng/ml, ns). No correlation was found between the two bone turnover markers: β CTX and BGP.

Comparisons between patients, divided according to the current dose of imiglucerase (<60 vs ≥ 60 IU/kg/2weeks (n = 6)), showed that mean β CTX levels were similar in both groups (662 ± 395 vs 685 ± 274 ng/ml, respectively), and mean BGP levels were lower in patients receiving the lower dose (19.3 ± 7.5 vs 27.2 ± 15.9 ng/ml, respectively), though the difference failed to reach statistical significance.

A strong correlation was observed between both bone turnover marker levels, β CTX and BGP, and levels of Ch-P1 activity ($r: 0.81$, $p < 0.02$ and $r: 0.80$, $p < 0.02$; respectively).

No differences in bone mass, body composition or bone marker values were observed when comparing patients according to presence or absence of splenectomy, hepatomegaly, bone crises, bone pain and history of osteoporotic fractures.

DISCUSSION

The GDI patients studied herein presented a decrease in bone mass, and significant changes in body composition (reduced BMD, BMC, FM and LM). It is known that the incidence of osteoporotic fractures is nega-

tively related to BMD. Epidemiological studies indicate that the risk of osteoporotic fractures increases continuously as BMD declines, (Cummings et al. 1993), and it is well documented that body composition components influence bone mass (Michaelsson et al. 1996; Sundeeep et al. 1996; Matsuo et al. 2003; Makovey et al. 2005; Walsh et al. 2006).

Correlations observed between LM and bone mass parameters suggest that the decrease in LM could be another determining factor of low bone mass in GDI patients.

Hypermetabolism was previously described in GDI patients, as evidenced by an increase in glucose production, and REE (Corssmit et al. 1995) (Hollak et al. 1997). In other diseases, such as hyperthyroidism, patients present an hypermetabolic state (Loeb 1996), and similar alterations in body composition (reduced BMC, BMD, FM, and LM; Gómez Acotto et al. 2002). It is noteworthy that specific treatment significantly reduced this hypermetabolic state in both pathologies, i.e. Gaucher disease and hyperthyroidism (Loeb 1996; Hollak et al. 1997; Alfonso et al. 2003). Body composition alterations can be reversed in patients attaining euthyroidism (Gómez Acotto et al. 2002), and it could indirectly explain why GDI patients treated with the higher dose of ERT were less affected. Analysis of the impact of ERT on body composition and bone mass showed that the decrease in bone mass and lean mass was less marked in patients receiving a higher monthly dose. In their study on 12 GDI adult patients (10 patients were receiving ERT), Fiore et al. (Fiore et al. 2002) observed severe osteopenia in both total skeleton and lumbar spine. The dose received by those patients ranged between 30 and 60 IU/kg/2w during 2-8 years; however, it must be pointed out that the data

were not presented according to dose or duration of treatment. Rosenthal's study on bone mass in a small group of patients by means of quantitative tomography showed that bone density improved after approximately 3 and a half years of ERT, suggesting that a longer treatment is necessary for skeletal alterations to improve compared with the length of treatment required for recovery of hematological alterations (Rosenthal et al. 1995). A recent study by Wenstrup performed in a large cohort of GDI patients from the International Gaucher Registry (Wenstrup et al. 2007), showed that ERT with imiglucerase may increase lumbar spine BMD after long term treatment; however, not all their patients achieved normal BMD values (age- and sex-adjusted).

The results presented herein are in agreement with findings reported by Ciana et al., who found no relation between bone density at any site and GDI clinical dichotomous variables: splenectomy status, hepatomegaly status, history of osteoporotic fractures, osteonecrosis, or bone crises (Ciana et al. 2003). Conversely, Pastores et al. (Pastores et al. 1996) reported higher bone mass diminution in patients with splenectomy or hepatomegaly. It is possible that a relation cannot be established in the present study on account of the small study population.

The pathogenesis of bone changes in GDI is not fully understood and it is currently attributed to the combined effects of progressive marrow infiltration by the Gaucher cells, and macrophage enhancement of endothelial-mediated resorption. This is suggested by the evidence of local cytokine release in Gaucher cell cultures, as well as by the increase in serum levels of certain cytokines, such as interleukin-6 (IL-6), which stimulates bone resorption, and IL10, an inhibitor of osteoblastic activity (Gery et al. 1981; Balicki et al. 1995; Michelakakis et al. 1996; Allen et al. 1997; Allen et al. 1999).

Bone formation and bone resorption can be assessed non-invasively by measuring biochemical markers of bone turnover that can provide an insight into the pathogenesis of osteopenia /osteoporosis (Eastell et al. 1993; Valimaki et al. 1994). In the present study, alterations in bone turnover observed in GDI patients, in spite of ERT, could be attributed to an increase in resorption, since formation was similar to that of controls. BGP values did not differ from those of healthy sex and age-matched controls. Conversely, serum levels of β CTX, a marker of bone resorption, exhibited a significant increase in GDI patients, demonstrating an imbalance between both processes. The prevalence of resorption over formation may cause a continuous loss of bone mass, leading to osteopenia and osteoporosis. Several studies have confirmed a disturbance of the normal balance between bone formation and resorption in GDI patients. In agreement with the present study, Fiore et al. reported an increase in bone resorption markers, and normal bone formation markers in GDI patients without ERT (Fiore et al. 2002). However, Drugan et al. reported a reduction in bone turnover markers (BGP and β CTX) in 16 patients without ERT (Drugan et al. 2002). Finally, in a study performed on patients prior to initiating ERT treatment, Ciana et al. (Ciana et al. 2003) showed uncou-

pled bone remodeling that depended on the sensitivity of each marker.

Some histomorphometric studies of bone biopsies, a gold standard to evaluate changes in bone metabolism, performed in Gaucher patients without ERT, have shown an increase in bone resorption (Stowens et al. 1985; Ostlere et al. 1991).

The results obtained in the present group of GDI patients, using DXA, showed alterations in body composition parameters. To our knowledge, there are no previous reports evaluating body composition of GDI patients by means of DXA. The observed alterations may be the result of a hypermetabolic state, which may also be implicated in the physiopathology of osteopenia/osteoporosis in GDI patients.

In agreement with previous studies the group of GDI patients studied herein showed a significant decrease in bone mass associated to uncoupled bone turnover with high resorption, in spite of ERT.

The alteration in body composition parameters described in this study, mainly decreased lean mass, may also be implicated in the physiopathology of osteopenia/osteoporosis in GDI patients.

It is necessary to conduct further longitudinal studies on larger population in order to elucidate whether this uncoupling in bone remodeling and the alterations in body composition are determinants of the decrease in bone mass.

Acknowledgments: We thank Julia Somoza for her technical assistance, the physicians who collaborated in the recruitment of the patients, and Genzyme laboratory for performing determinations of chitotriosidase activity. This work was partially supported by the "Fundación de Osteoporosis y Enfermedades Metabólicas Óseas" (FOEMO) and the Argentine National Agency for the Promotion of Science and Technology (ANPCYT).

REFERENCES

1. Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakash-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ: International Collaborative Gaucher Groups U.S. Regional Coordinators. Individualization of long-term enzyme replacement therapy for Gaucher Disease. *Genet Med.* 2005; 7:105-10.
2. Alfonso P, Cenarro A, Perez-Calvo JI, Puzo J, Giral M, Giraldo P, Pocovi M. Effect of enzyme replacement therapy on lipid profile in patients with Gaucher's disease. *Med Clin (Barc).* 2003; 120: 641-6.
3. Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM. Pro-inflammatory cytokines and the pathogenesis of Gaucher disease: increased release of interleukin-6 and interleukin-10. *Q J Med.* 1997; 90: 19-25.
4. Allen MJ, Hollak CEM, Evers L, Aerts JM, and van Oers MHJ: Elevated level of MCSF, sCD 14 and IL6 in type I Gaucher disease. *Blood Cells Mol Dis.* 1999; 23: 201-12.
5. Balicki D, Beutler E. Gaucher disease. *Medicine (Baltimore).* 1995; 74: 305-23.
6. Baumgartner RN, Stauber PM, Koehler KM, Romero L, Garry PJ. Associations of fat and muscle masses with bone mineral in elderly men and women. *Am J Clin Nutr.* 1996; 63: 365-72.
7. Bembi B, Ciana G, Mengel E, Terk MR, Martini C, Wenstrup RJ. Bone complications in children with Gaucher disease *Br J Radiol.* 2002; 75 (Suppl 1): A37-A44.

8. Boot RG, Renkema GH, Strijland A, van Zonneveld AJ, Aerst JM. Cloning of cDNA encoding chitotriosidase, a human chitinase produced by macrophages. *J Biol Chem.* 1995; 270: 26252-6.
9. Cenarro A, Pocovi M, Giraldo P, Garcia-Otin AL, Ordovas JM. Plasma lipoprotein responses to enzyme-replacement in Gaucher's disease. *Lancet.* 1999; 353: 642-3.
10. Ciana G, Martini C, Leopaldi A, Tamaro G, Katouzian F, Ronfani L, Bembi B. Bone markers alterations in patients with type 1 Gaucher disease. *Calcif Tissue Int.* 2003; 72: 185-9.
11. Ciana G, Addobbati R, Tamaro G, Leopaldi A, Nevyjel M, Ronfani L, Vidoni L, Pittis MG, Bembi B. Gaucher disease and bone: laboratory and skeletal mineral density variation during a long period of enzyme replacement therapy. *J Inherit Metab Dis.* 2005; 28: 723-32.
12. Cohen IJ, Katz K, Kornreich L, Horev G, Frish A, Zaizov R. Low-dose high frequency enzyme replacement therapy prevents fractures without complete suppression of painful bone crisis in patients with severe juvenile onset type I Gaucher disease. *Blood Cells Mol Dis.* 1998; 24: 296-302.
13. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Voght TM. Bone density at various sites for prediction of hip fractures The Study of Osteoporotic Fractures Research Group. *Lancet.* 1993; 341: 72-5.
14. Corssmit EPM, Hollak CEM, Endert E, van Oers MHJ, Sauerwein HP, Romijn JA. Increased basal glucose production in Type I Gaucher's disease. *J Clin Endocrinol Metab.* 1995; 80: 2653-7.
15. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R. Estimates of optimal vitamin D status. *Osteoporosis Int.* 2005; 16: 670-6.
16. Drugan C, Jelebeanu G, Grigorescu-Sido P, Caillaud C, Craciun AM. Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease. *Blood Cells Mol Dis.* 2002; 28: 13-20.
17. Eastell R, Robins SP, Colwell T, Assiri AM, Riggs BL, Russell RG. Evaluation of bone turnover in Type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. *Osteoporosis Int.* 1993; 3: 255-60.
18. Fiore CE, Barone R, Pennisi P, Pavone V, Riccobens S. Bone ultrasonometry, bone density, and turnover markers in type I Gaucher disease. *J Bone Miner Res.* 2002; 20: 34-8.
19. Gery L, Zigler JS, Brady RO, Barranger JA. Selective effects of glucocerebrosidase (Gaucher's storage material) on macrophage cultures. *J Clin Invest.* 1981; 68: 1182-8.
20. Hollak CEM, Corssmit EPM, Aerts JMFG, Endert E, Sauerwein HP, Romijn JA, van Oers MHJ. Differential effects of enzyme replacement therapy on manifestations of Type I Gaucher disease. *Am J Med.* 1997; 103: 185-91.
21. Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ, Tayebi N, Sidransky E. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. *Am J Hum Genet.* 2000; 66: 1777-86.
22. Lebel E, Dweck A, Foldes AJ, Golowa Y, Itzchaki M, Zimran A, Elstein D. Bone density changes with enzyme therapy for Gaucher disease. *J Bone Miner Metab.* 2004; 22: 597-601.
23. Lim S, Joung H, Shin SC, Lee HK, Kim KS, Shin EK, Kim HY, Lim MK, Cho SI. Body composition changes with age have gender-specific impacts on bone mineral density. *Bone.* 2004; 35: 792-8.
24. Makovey J, Naganathan V, Sambrook P. Gender differences in relationships between body composition components, their distribution and bone mineral density: a cross-sectional opposite sex twin study. *Osteoporosis Int.* 2005; 16: 1495-505.
25. Matsuo T, Douchi T, Nakae M, Uto H, Oki H, Nagata Y. Relationship of upper body fat distribution to higher regional lean mass and bone mineral density. *J Bone Miner Metab.* 2003; 21: 179-83.
26. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. *JAMA.* 1999; 281: 249-54.
27. Michaelsson K, Bergstrom R, Mallmin H, Holmberg L, Wolk A, Ljunghall S. Screening for osteopenia and osteoporosis: selection by body composition. *Osteoporosis Int.* 1996; 6: 120-6.
28. Michelakakis H, Spanou C, Konyli A, Dimitriou E, Van Weely S, Hollak CE, Van Oers MH, Aerts JM. Plasma tumor Necrosis Factor alpha (TNF alpha) levels in Gaucher disease. *Biochim Biophys Acta.* 1996; 1317: 219-22.
29. Oliveri B, Zeni S, Lorenzetti MP, Aguilar G, Mautalen CA. Effect of one year residence in Antarctica on Bone mineral Metabolism and body composition. *Eur J Clin Nutr.* 1999; 53: 88-91.
30. Ostlere L, Warner T, Meunier PJ, Hulme P, Hesp R, Watts RWE, Reeve J. Treatment of Type 1 Gaucher's Disease Affecting Bone with Aminohydroxypropylidene Bisphosphonate (Pamidronate). *QJ Med.* 1991; 79: 503-5115.
31. Pastores GM, Wallenstein S, Desnick RJ, Luckey MM. Bone density in type I Gaucher disease. *J Bone Miner Res.* 1996; 11: 1801-7.
32. Pluijm SMF, Visser M, Smit JH, Popp-Snijders C, Roos JC, Lips P. Determinants of bone mineral density in older men and women: Body composition as mediator. *J Bone Miner Res.* 2001; 16: 2142-51.
33. Proctor DN, Melton III LJ, Khosla S, Crowson CS, O'Connor MK, Riggs L. Relative influence of physical activity, muscle mass and strength on bone density. *Osteoporosis Int.* 2000; 11: 944-52.
34. Reid IR, Lindsay D, Plank D, Evans MC. 1992 Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. *J Clin Endocrinol Metab.* 1992; 75: 779-82.
35. Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, McKusik KA, Rosen BR, Baker J, Niklason NW, Suvimol CH, Miller SP, Brady RO, Barton NW. Enzyme replacement therapy for Gaucher's disease: skeletal responses to macrophages-targeted glucocerebrosidase. *Pediatrics.* 1995; 96: 629-37.
36. Rudzki Z, Okori K, Machaczka M, Rucinska M, Papla B, Skotnicki AB. Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type 1 disease - a histological study. *Eur J Haematol.* 2003; 70: 273-81.
37. Schiffman R, Mankin H, Dambrosia JM, Xavier RJ, Kreps C, Hill SC, Barton NW, Rosenthal DI. Decreased Bone Density in splenectomized enzyme replacement therapy. *Blood Cells Molecules and diseases.* 2002; 28: 288-96.
38. Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA. Skeletal complications of Gaucher disease. *Medicine (Baltimore).* 1985; 64: 310-22.
39. Sundeep K, Atkinson E, Riggs L. Relationship between body composition and bone mass in women. *J Bone Miner Res.* 1996; 11: 857-63.
40. Valimaki MJ, Tahtela R, Jones JD, Peterson JM, Riggs BL. Bone resorption in healthy osteoporotic women: comparison markers of serum carboxy-terminal telopeptide of type I collagen and urinary pyridinium cross-links. *Eur J Endocrinol.* 1994; 131: 258-62.
41. Vega E, Bagur A, Mautalen CA: Densidad Mineral ósea en mujeres osteoporóticas y normales de Buenos Aires. *Medicina (Buenos Aires).* 1993; 53: 211-6.
42. Walsh MC, Hunter GR, Livingstone MB. Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. *Osteoporosis Int.* 2006; 17: 61-7.

43. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, Bembi B. Skeletal aspects of Gaucher disease: a review. *Brit Med J*. 2002; 75 (suppl 1): A2-A12.
44. Wenstrup RJ, Bailey L, Grabowsky GA, Moskovitz J, Oestreich AE, Wu W, Sun S. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. *Blood*. 2004; 104: 1253-7.
45. Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN. Effect of Enzyme Replacement Therapy with imiglucerase on BMD in Type I Gaucher Disease. *J Bone Miner Res*. 2007; 22 :19-26.
46. Wittich A, Oliveri MB, Rotemberg E, Mautalen C: Body composition of professional football (soccer) players determined by dual X ray absorptiometry. *J Clin Densitometry*. 2001; 4: 51-5.
47. Zeni S, Wittich A, Di Gregorio S, Casco C, Oviedo A, Somoza J, Gómez Acotto C, Bagur A, González D, Portela ML, Mautalen C: Utilidad Clínica de los marcadores de formación y resorción ósea. *Acta Bioquímica Clínica Latinoamericana*. 2001; 35: 3-36.

Received: April 6, 2007 / Accepted: November 15, 2007

Address for correspondence:

Muriel S Parisi, MD, PhD
Av. Córdoba 2351
8° piso (1120) Buenos Aires
Argentina
Tel./Fax: (54-11)5950-8972/73
E-mail: mparisi@hospitaldeclinicas.uba.ar
osteologia@hospitaldeclinicas.uba.ar